2010 journal article

Characterization of side population cells in human malignant mesothelioma cell lines

LUNG CANCER, 70(2), 146–151.

By: K. Kai n, S. D'Costa n, B. Yoon n, A. Brody n, R. Sills* & Y. Kim n

co-author countries: Japan 🇯🇵 Korea (Republic of) 🇰🇷
author keywords: Mesothelioma; Side population; Cancer stem cell; Hoechst 33342; Tumorigenicity; Flow cytometry
MeSH headings : Animals; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cisplatin / pharmacology; Feasibility Studies; Flow Cytometry; Gene Expression Regulation, Developmental; Humans; Mesothelioma / diagnosis; Mesothelioma / drug therapy; Mesothelioma / pathology; Mice; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells / drug effects; Neoplastic Stem Cells / metabolism; Neoplastic Stem Cells / pathology; Side-Population Cells / drug effects; Side-Population Cells / metabolism; Side-Population Cells / pathology
Source: Web Of Science
Added: August 6, 2018

2009 journal article

Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines

CANCER LETTERS, 278(1), 49–55.

By: K. Kai n, S. D'Costa n, R. Sills* & Y. Kim n

co-author countries: Japan 🇯🇵
author keywords: Malignant mesothelioma; Insulin-like growth factor 1 receptor; AG1024; Cisplatin; Chemoresistance
MeSH headings : Antineoplastic Agents / therapeutic use; Apoptosis / drug effects; Cell Division / drug effects; Cell Line, Tumor / drug effects; Cisplatin / therapeutic use; Humans; Mesothelioma / drug therapy; Pleural Neoplasms / drug therapy; Receptor, IGF Type 1 / antagonists & inhibitors; Signal Transduction / drug effects; Tyrphostins / therapeutic use
Source: Web Of Science
Added: August 6, 2018

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.